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http://dxObjective: The role of extended thymectomy in the treatment of class I myasthenia gravis is still controversial.
This study compared the long-term outcomes of operated and nonoperated patients allocated according to their
will.
Methods: We retrospectively reviewed 47 patients with class I nonthymomatous myasthenia gravis under-
going extended thymectomy between 1980 and 2007. These patients were matched with 62 class I patients
who refused surgery and received only pharmacologic therapy. Outcomes were stable remission and clinical
or pharmacologic improvement. Predictors of remission were analyzed by Kaplan–Meier and Cox re-
gression.
Results:We observed low postoperative major morbidity (n¼ 2; 4.2%) and no perioperative mortality. Hetero-
topic thymus was found in 22 patients (46%). Twenty-one patients showed active germinal centers, in the het-
erotopic thymus in 12 patients (57.1%). Thirty operated patients (64%) versus 34 nonoperated patients (55%)
achieved stable remission, and 8 patients (17%) versus 5 patients (9%) showed pharmacologic improvement.
Nine patients who had no postoperative improvement showed active ectopic thymus. Surgery was a marginal
prognosticator (P ¼ .053). Early treatment (6 months from symptoms onset) was the unique significant prog-
nosticator (P¼ .045), but this was due to the contribution of the operated patients (P¼ .002). Other predictors of
remission in the operated group were the absence of ectopic thymus (P ¼ .007) with no germinal centers
(P ¼ .009). No significant predictor of remission was found in the nonoperated group.
Conclusions: Extended thymectomy achieved a more rapid remission than after nonsurgical treatment of class I
myasthenia gravis. Significantly better outcomes resulted when thymectomy was performed within 6 months
from the onset of symptoms. (J Thorac Cardiovasc Surg 2013;145:1319-24)G
T
SClass I myasthenia gravis (MG) is characterized by distur-
bances limited to the oculomotor and levator palpebrae
muscles, causing diplopia and ptosis, while all other muscle
strength is normal. Approximately one third of all patients
with MG are diagnosed with class I.1 MG remains purely
ocular in 15% of cases,2 but approximately one half of pa-
tients will progress within 2 years.3 Myasthenic thymus
usually shows histologic alterations varying from lymphoid
hyperplasia to atrophy or tumor.4 The production of autoan-
tibodies by thymic B-cells is the basis of MG pathogenesis.5
The opportunity of thymectomy in class I MG is cur-
rently debated, some studies supporting6,7 and others
opposing its effectiveness.8,9 The relative rarity of this
clinical condition prevents the collection of large series.
Thus, we retrospectively compared the outcomes of
patients who underwent extended thymectomy for class I
MG with those treated only with medical therapies.e Department of Thoracic Surgery, Multidisciplinary Myasthenia Gravis
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The Journal of Thoracic and CarMATERIALS AND METHODS
Patients
From 1980 to 2007, a total of 136 patients diagnosed with class I MG
according to theMG Foundation of America10 and with no evidence of me-
diastinal mass were studied in our dedicated multidisciplinary MG unit.
Neurologists with extensive experience in MG formulated the diagnosis,
which was based on clinical features consisting of oculomotor and levator
palpebrae muscle weakness originating from binocular diplopia and asym-
metric ptosis. Features also included 1 or both of the following: (1) muscle
strength improvement after edrophonium chloride administration and (2)
primary postsynaptic disorder tested by repetitive nerve stimulation or
single-fiber electromyography. Patients diagnosed after 1994 also were
tested for circulating anti–acetylcholine receptor (AChR) antibodies. Com-
puted tomography of the chest was performed in all patients. After panel
consultation, extended thymectomy was proposed to 128 patients. Patients
were informed about the lack of consensus regarding surgery in class I non-
thymomatous MG. After providing the patients with exhaustive informa-
tion about the pros and cons and long-term results of surgery versus no
surgery, the patients were asked to make a decision. Sixty-six patients
chose surgical treatment. None of them received specific medical therapy
(ie, anticholinesterase agent or corticosteroids) before surgery. Both oper-
ated and nonoperated patients were followed by the same medical staff in
the Multidisciplinary Myasthenia Gravis Unit.
Study Design
This was a retrospective study comparing patients with class I MG who
underwent thymectomy followed by medical therapy with patients treated
only with medical therapy. As reported in the previous section, the 2 groups
were generated by a self-allotment criteria based on the patient’s
preference.
The review study was authorized by the ethical committee and institu-
tional review board of Tor Vergata University and activated in 2010.diovascular Surgery c Volume 145, Number 5 1319
Abbreviations and Acronyms
AChR ¼ anti–acetylcholine receptor
MG ¼ myasthenia gravis
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SWritten and fully informed consent to the use of personal data was obtained
from each patient involved in the study. The incidental discovery of an un-
expected thymoma implied exclusion from the study (n ¼ 19). Clinical in-
formation was retrieved from the MG unit database collected during
hospital admissions. Patients undergoing operation before 2000 and there-
fore classified according to Osserman11 were retrospectively reclassified.
Patients’ recruitment was interrupted in 2007 to have a minimum follow-
up of at least 5 years.
Surgical Group
A total of 47 patients underwent extended thymectomy via median ster-
notomy by the same surgeon (TCM). Demographic data are summarized in
Table 1.
The operation was accomplished under general anesthesia with
single-lung ventilation. All procedures were preceded by the insertion
of an arterial line and a central venous catheter. Electrocardiogram, non-
invasive blood pressure, pulse oximetry, end-tidal carbon dioxide, airway
pressure, ventilatory volume, and fraction of inspired oxygen were rou-
tinely monitored. Only short-acting, nondepolarizing neuromuscular re-
laxants were occasionally used. The thymus was approached via a total
median sternotomy defined as T-3b according to the MG Foundation of
America.12 Resection routinely included the thymus gland, perithymic
adipous tissue, perithymic cervical, perithyroid and retroinnominate
vein regions, and fatty tissue in the aortocaval groove, the aortopulmo-
nary window, and both pericardiophrenic sinuses. Thymectomy was con-
sidered extended according to Sonnet and Jaretzki.13 In the postoperative
period, an anticholinesterase agent or corticosteroids were started when
necessary.
Thymic Specimen Evaluation
Thymic and extrathymic tissues were routinely examined. Hematoxy-
lin–eosin-stained sections were prepared from paraffin-embedded blocks
and examined under low magnification (320). Ectopic thymus was
searched by randomly sampling 1 of every 5 sections of fat tissue inclu-
sions. Germinal centers were detected by examining visual fields of at least
5 sections of the thymus stained with monoclonal antibodies against
CD23.14 Cytoplasmic staining with anti-human CD23 was scored as posi-
tive by an experienced pathologist.
Follow-up
Patients were visited for follow-up in the dedicatedMG unit by the same
team of physicians at 3 months after the first year and then every 6 months.
Other information was obtained by telephone. Medication (ie, anticholin-
esterase or steroids) and dosage in the 2 groups were timely recorded.
The dose of medications was progressively reduced and eventually with-
drawn if the patient became symptom-free. No immunosuppressive drug
was used.
The therapeutic effect and symptomatic response to the different thera-
pies was established for each patient according to the MG Foundation of
America postinterventus status classification.10 Stable remission was de-
fined as no symptoms or signs of ocular MG at careful examination for
at least 12 months achieved without therapy, except for low-dose steroids
(10 mg/d methylprednisolone). This caveat was adopted to define com-
plete remission, given that in a few instances the neurologists administered
occasional low-dose corticosteroids despite the disappearance of symp-
toms for more than 1 year.7,151320 The Journal of Thoracic and Cardiovascular SurImprovement was defined as amelioration of ocular symptoms (clinical)
or a long-lasting decrease in MG therapy (pharmacologic). Patients whose
ocular symptoms or administered medication dosages were stable were
scored as ‘‘unchanged.’’ Likewise, those patients who developed more se-
rious ocular symptoms or required an increase in medical therapy, or whose
symptoms progressed toward the other classes, were all defined as having
‘‘worsened disease.’’
Statistical Analysis
Values of descriptive variables were presented as median (inter-
quartile range). All analyses were performed with the Statistical Pack-
age for the Social Sciences (SPSS Inc, Chicago, Ill). Because of the
relatively small sample size compared with the multiplicity and the
non-normal distribution of the investigated variables, the nonparametric
tests were prudentially used. In a preliminary step, the homogeneity of
the 2 groups was tested for demographic features and main disease-
related variables. The interdependence between the principal clinical
variables and the outcomes was evaluated in each group by univariate
analysis.
Thereafter, the effect of each variable on stable remission was deter-
mined by the Kaplan–Meier estimates of time to stable remission at spe-
cific time points. Time to stable remission was defined as the time
between the day of surgery or the beginning of medical treatment, and
the date of stable remission. Patients who had not achieved stable remis-
sion were censored. Multivariate analysis of the entire population to se-
lect the most significant predictor of remission was conducted by Cox
regression analysis.
RESULTS
The 2 groups were homogeneous for all demographic and
clinical variables investigated as shown inTable 1. Therewas
no perioperative mortality in the operated group, whereas
major morbidity was experienced in 2 patients (4.2%): 1
case of sternal infection and 1 case of pneumonia and pleural
effusion. No myasthenic crisis occurred after surgery.
Histologic examination showed hyperplasia in 27 pa-
tients (58%) and normal thymus in 20 patients (42%). In
these specimens, germinal centers were detected in 21 of
the native thymuses (45%): 12 (12/27, 44%) hyperplastic
and 9 (9/20, 45%) normal. Heterotopic thymic tissue was
found in 22 patients (47%) and was more frequent in the
normal atrophic (12/20, 60%) than in the hyperplastic
(10/27, 37%) native thymus. This tissue was located in
the cervical region (n¼ 10, 45%), aortopulmonary window
(n ¼ 5, 22%), anterior mediastinum (n ¼ 18, 81%), and
right (n ¼ 1, 5%) and left (n ¼ 2, 9%) pericardiophrenic
angles; 14 patients had ectopic thymic tissue at 2 different
sites. Presence of germinal centers was proved in more than
one half (12/22, 54%) of the patients with ectopic thymus.
Long-Term Results
Complete follow-up was available in all patients
(Table 1). Two patients died at 45 and 96 months from the
operation. In both cases, death was related to cardiovascular
disease. Four patients died in the nonoperated group, 2 of
them as the result of complications related toMGworsening.
The analysis of prescribed medications initially docu-
mented a lower median dosage for both anticholinesterasegery c May 2013
FIGURE 1. Median dosage changes in both study groups for anticholin-
esterase (top) and steroid (bottom) drugs.
TABLE 1. Clinical features of the two groups (operated vs nonoperated)
Clinical features Operated (n ¼ 47) Nonoperated (n ¼ 62) P value
Age, median y (IQR) 19 (16-24) 19 (16-25) .380
Early onset 16 y vs>16 y 14 vs 33 16 vs 46 .646
Sex, male vs female 17 vs 30 21 vs 41 .804
Symptom-therapy interval, median mo (IQR) 6 (4-21) 6 (4-23) .860
Early treatment 6 mo vs>6 mo 22 vs 25 24 vs 38 .397
AChR antibody dosage at diagnosis, median nmol/L (IQR)* 17 (13-21) 19 (15-26) .690
Follow-up, median mo (IQR) 100 (70-178) 116 (80-160) .973
1-y global improvement, no. of patients (%) 10 (21%) 5 (8%) .048
1-y MGFA class progression, no. of patients (%) 6 (13%) 13 (26%) .266
5-y global improvement, no. of patients (%) 27 (58%) 21 (34%) .035
5-y MGFA class progression, no. of patients (%) 9 (19%) 16 (26%) .413
Total stable remission rate, no. of patients (%) 30 (64%) 34 (55%) .347
Time to remission, median mo (IQR) 17 (5-29) 36 (29-48) .032
IQR, Interquartile range; AChR, anti–acetylcholine receptor; MGFA, Myasthenia Gravis Foundation of America. *Eight-six patients available.
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Sand steroid drugs in the operated group. This difference at-
tenuated after 5 years of follow-up (Figure 1).
In the operated group, 30 patients (64%) achieved stable
remission and 8 patients (17%) showed clinical or pharma-
cologic improvement. The remaining 9 patients (19%) expe-
rienced worsening of the symptoms with class progression.
Of note, all these cases presented active ectopic thymic islets
in the resected mediastinal fat and higher median titer of
AChR antibodies than the other operated patients. The me-
dian (interquartile range) value of AChR antibodies was as
follows: 24 (11-34) nmol/L versus 4 (0-9) nmol/L
(P ¼ .02) at 6 months, 25 (8-36) nmol/L versus 5 (0-10)
nmol/L (P¼ .03) at 12months, and 27 (10-38) nmol/Lversus
3 (0-5) nmol/L (P ¼ .02) at 24 months, respectively. In the
nonoperated group, 34 patients (55%) achieved stable remis-
sion and clinical symptoms improved or prescription dosages
were reduced in 5 patients. Progression to generalized
MG was observed in 16 patients (26%), whereas 3 patients
(48%) remained only with ocular symptoms. None of these
patients underwent thymectomy during the study period.
Likewise, the proportion of patients who improved
was significantly higher in the operated group: 21% versus
8% at 1 year (P ¼ .048) and 58% versus 34% at 5 years
(P¼ .035) (Table 1). The impact of main prognostic factors
on improvement in operated and nonoperated patients is
summarized in Table 2.
In the whole study population, Kaplan–Meier analysis
showed a more rapid positive outcome of operated versus
nonoperated patients with earlier median time to stable re-
mission (17 vs 36 months) and greater estimated rate of re-
mission at 5 years (53% vs 32%). Only early treatment (6
months) was a significant predictor (P ¼ .045) of stable re-
mission, whereas surgery was a marginal prognostic factor
(P¼ .053) (Figure 2). However, the positive impact of early
treatment was only due to the weight of ‘‘early operated’’
patients (P ¼ .002) and not to ‘‘early treated’’ nonoperated
patients (P ¼ .51). Indeed, early surgery allowed remission
in 77% of the cases.The Journal of Thoracic and CarIn the operated group, the presence of ectopic thymus
(P ¼ .007), especially with concomitant germinal centers
(P¼ .009), was found to be a significant negative predictordiovascular Surgery c Volume 145, Number 5 1321
TABLE 2. Interdependence between risk factors and clinical improvement in each study group
Operated
Postoperative status
P value
Nonoperated
Posttreatment status
P valueImproved Unchanged or worsened Improved Unchanged or worsened
Sex
Male 13 4 .52 12 9 .58
Female 25 5 27 14
Early onset
16 y 12 2 .58 13 3 .08
>16 y 26 7 26 20
Early treatment
6 mo 19 3 .36 16 7 .43
>6 mo 19 6 23 16
Histology
Hyperplasia 22 5 .89 NA NA
Normal 16 4 NA NA
Germinal centers
No 24 2 .02 NA NA
Yes 14 7 NA NA
Ectopic thymic tissue
No 25 — .0001 NA NA
Yes 13 9 NA NA
Ectopic active tissue
No 16 — .0001 NA NA
Yes — 9 NA NA
NA, Not applicable.
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Sof remission. No significant factor predicting stable remis-
sion was found in the nonoperated group.
Cox regression analysis showed that early treatment (6
months) was the most significant predictor of remission
(P ¼ .026). Noteworthy surgical therapy was a positive
prognostic factor if survival analysis was restricted to 5
years follow-up (P ¼ .041) (Table 3). The reasonableFIGURE 2. Kaplan–Meier remission curve for operated and nonoperated
patients.
1322 The Journal of Thoracic and Cardiovascular Surexplanation is that those patients who benefit from massive
thymic tissue removal improve within the first 5 years. Con-
versely, the probability of remission becomes less likely af-
ter 5 years. The late censorship of these subjects might have
affected statistical results shading the positive effect of
thymectomy.DISCUSSION
Although thymectomy is considered an integrated action in
the treatment of AChR antibody–positive MG, in subjects
with ocular symptoms only, surgery is difficult to accept.16,17
Thymectomy is usually performed to control or stop
symptoms, to avoid the possible progression of the disease,
and to reduce the intake of pharmacologic therapy,
minimizing unpleasant side effects. However, the mildness
of symptoms in class I MG often leads both neurologists
and patients to avoid surgery.8,9 In addition, the relative
rarity of the disease is still an obstacle in the collection of
a larger seriesand the setupof prospective randomizedstudies.
Nevertheless, there is a strong rationale for thymectomy
even in class IMG. In this class, there is a consistent produc-
tion of AChR antibodies in more than 50% of the patients.3
Antibody production often takes place in the noninvoluted
thymic gland.18,19 Many studies suggest that the synthesis
of AChR antibodies is likely situated in the activated
thymic regions (eg, B-cell follicles and germinal centers),
where B-lymphocytes differentiate into cells producing
antibodies with high affinity toward antigens.20-22gery c May 2013
TABLE 3. Cox regression analysis
Selection Variables B SE Wald P value Exp(B)
95% CI
Lower Upper
Unlimited follow-up Operated vs nonoperated 0.407 0.252 2.612 .106 1.502 0.917 2.459
Symptom-treatment interval (6 mo vs>6 mo) 0.561 0.252 4.979 .026 1.753 1.071 2.870
5-y follow-up Operated vs nonoperated 0.621 0.328 3.579 .041 1.861 0.978 3.540
Symptom-treatment interval (6 mo vs>6 mo) 0.370 0.319 1.347 .246 1.448 0.775 2.703
SE, Standard error; CI, confidence interval.
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SRemoval of as much thymic parenchyma as possible and the
active tissue should be an effective treatment.
Our investigations demonstrated several relevant points.
First, extended thymectomy proved safe and effective to
achieve stable remission. We observed no mortality and
a low rate of major morbidities. Surgery had a more rapid
effect than pharmacologic therapy, and this was supported
by the shorter median time to remission. When the analysis
was restricted to the first 5 years from treatment, more than
one half of our operated patients achieved stable remission,
and this rate is similar to the most encouraging series in the
literature.23-25
Second, the clinical-pharmacologic improvement was
comparatively delayed in the nonoperated group, and these
patients experienced a greater probability of progression to-
ward more severe classes of MG. This finding could be ev-
idence that pharmacologic therapy is less effective in
counteracting the natural history of the disease.
Third, in partial contrast with other studies,26 in the cur-
rent study, surgical procedure did not completely protect
from MG progression. Indeed, 20% of the thymectomized
patients had disease progression within 1 year from surgery.
This event is strictly correlated to the presence of active ec-
topic tissue and is characterized by a increment of AChR an-
tibody titer. Zuckerman and colleagues27 have recently
reported that heterotopic active thymic islets can be present
in adjacent mediastinal areas. Ponseti and colleagues28 sug-
gested that their persistence may impair the symptomatic
improvement after thymectomy in any class. In a previous
article about class III MG, we discussed the prognostic im-
portance of ectopic thymic tissue, which may frequently
host germinal centers.14 The production ofAChR antibodies
could take place specifically in these areas as a result of
a dysregulated autoimmune response to epithelioid cells.
This suggests the critical role of germinal centers in the path-
ogenesis ofMG.20,21 The presence of this actively antibody-
producing thymic tissue may coexist with a normal thymus
and correlates to worse outcome after thymectomy. These
patients should receive more aggressive clinical strategy
with closer follow-up, preventive use of immunosuppressive
drugs, and eventually reoperation. The elevated failure rate
after surgery demonstrates the difficulty of achieving a total
clearance from ectopic foci despite an extensive operation.
A question arises from this finding about opportunity of
a transsternal approach in a poor symptomatic disease. ItThe Journal of Thoracic and Carsuggests that a minimally invasive thymectomy seems to
be more appropriate in patients with class I MG.
Finally, both univariate and multivariate analyses indi-
cate that extended thymectomy has the best results when
performed within the first 6 months from the onset of ocular
symptoms. More than three quarters of the patients under-
going operation within 6 months achieved remission.
Only one half of those with a longer interval experienced
the same positive outcome. We hypothesize that early treat-
ment prevents the establishment of active heterotopic ger-
minal centers.
Study Limitations
The retrospective nature of the study represents the major
obvious limitation. The arbitrary criteria of allocation of the
2 groups based on patients’ auto-determination is another
limitation. However, this method is reasonable for a disease
lacking universally accepted therapeutic guidelines. This
method was approved and authorized by our internal ethical
committee. Despite the empiric allotment criteria, the 2
groups were statistically homogeneous in all clinical fea-
tures investigated. Another limit, due to the relative rarity
of the condition, is the wide timespan required to gather
a consistent sample size. Nevertheless, our study provides
valuable data based on an experienced single surgeon who
always performed an intentional extended thymectomy.
Last, the exemption of occasional low-dose steroids for
complete remission may have a benefit on time to remission
and evoke some criticism about data interpretation. How-
ever, this caveat was already used in the literature7,15 and
was adopted for the evaluation of both groups; therefore,
it does not produce a bias when comparing the outcomes
of the 2 treatments.
CONCLUSIONS
Early diagnosis (6 months) in nonthymomatous class I
MG is the most significant predictor of stable remission. Ex-
tended thymectomy achieved a more rapid remission than
nonsurgical treatment of class I MG. Significantly better
outcomes resulted when the operation was performed
within 6 months from the diagnosis with an impact on the
natural history of the disease. We still agree with the
20-year-old statement by Buckingham and colleagues29:
‘‘It seems likely that future discoveries will permit the man-
agement of MG without surgical intervention, but, for thediovascular Surgery c Volume 145, Number 5 1323
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Spresent, the biological role of thymectomy for these unfor-
tunate patients has been widely demonstrated.’’ Future stud-
ies may validate new therapeutic measures, but at present
thymectomy remains the best way to approach class I non-
thymomatous MG.
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